Do complement pathways play a role in kidney diseases affecting my transplant?
Complement pathways are part of your immune system that help fight infection, but they can also cause damage if they become overactive. In kidney transplantation, complement activation can contribute to injury of the transplanted kidney, especially during rejection episodes. Research shows that complement plays a role in both early injury after transplant and in long-term rejection, and new treatments are being studied to block this process.
What the research says
The complement system has three main activation pathways: classical, lectin, and alternative 1. In kidney transplantation, complement is activated during ischemia-reperfusion injury (the damage that occurs when blood flow returns to the kidney after transplant) and can influence delayed graft function 6. Complement also plays a role in both acute cellular rejection and antibody-mediated rejection (ABMR) 6. A 2022 study found that complement markers C3d and C4d deposition in kidney biopsies are strong indicators of active ABMR, while terminal complement component C5b-9 was only weakly expressed 8. This suggests that complement activation is important in ABMR, but the full cascade may not always be completed. Additionally, genetic mutations in complement regulatory proteins (like factor H, MCP, and factor I) are linked to hemolytic uremic syndrome after transplant 7. Because of this, complement is being explored as a therapeutic target in kidney transplant 16. For example, a phase 2 study is testing abatacept, a drug that may affect immune pathways, in kidney transplant recipients 5. While not all sources directly address complement in transplants, the evidence consistently points to complement as a key player in transplant-related kidney diseases.
What to ask your doctor
- Could complement activation be contributing to my transplant rejection or kidney function decline?
- Are there any tests (like C3d or C4d staining on biopsy) that can show complement involvement in my case?
- Should I be evaluated for genetic complement abnormalities if I have had atypical hemolytic uremic syndrome or recurrent rejection?
- Are there any complement-targeting treatments available or in clinical trials that might be appropriate for me?
- How does complement activity relate to my current immunosuppression and risk of infection?
This question is drawn from common patient questions about Nephrology and answered using cited medical research. We do not provide individualized advice.